Novel role of myeloid-derived lymphatic progenitors in induction of breast cancer lymphatics
髓源性淋巴祖细胞在诱导乳腺癌淋巴管中的新作用
基本信息
- 批准号:9194058
- 负责人:
- 金额:$ 33.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-07-01 至 2021-05-31
- 项目状态:已结题
- 来源:
- 关键词:Adoptive TransferBloodBlood VesselsBone MarrowBone Marrow TransplantationBreast Cancer ModelBreast Cancer PatientBreast cancer metastasisCancer PatientCell LineageCellsChimera organismClinicalComplementDataDetectionEnvironmentEpithelialGenerationsHumanITGAM geneImmature BoneIn VitroInflammation MediatorsInflammatoryLigandsLymphLymphangiogenesisLymphaticLymphatic Endothelial CellsLymphatic MetastasisLymphatic Vessel TumorsLymphatic vesselMammary NeoplasmsMediatingMetastatic Neoplasm to Lymph NodesMetastatic breast cancerMethodsModelingMolecularMolecular TargetMusMyelogenousMyeloid CellsNF-kappa BNeoplasm MetastasisOrganOutcomeOutcome StudyPathway interactionsPatientsPharmaceutical PreparationsPhenotypeProcessPrognostic MarkerProteinsRecruitment ActivityRoleSignal TransductionStem cellsTLR4 geneTestingUp-RegulationValidationVascular Endothelial Growth Factor CVascular Endothelial Growth Factor Receptor-3Vascular Endothelial Growth Factorsautocrinebaseclinically significantdensityimprovedin vivolymph nodesmalignant breast neoplasmmonocytemortalityneoplastic cellnovelparacrinepodoplaninpreventprogenitorreceptortraittranscription factortransdifferentiationtumorvasculogenesis
项目摘要
PROJECT SUMMARY/ABSTRACT
Title: Novel Role of Myeloid-derived Lymphatic Progenitors in Induction of Breast Cancer Lymphatics
Metastasis to lymph nodes, a common occurrence in breast cancer (BC), is the most significant prognostic
indicator of poor outcome. To reach locoregional lymph nodes, tumor cells exclusively use lymphatic vessels.
Not surprisingly, the extent of lymphatic metastasis is directly proportional to the density of tumor lymphatic
vessels. It is therefore of high clinical significance to understand the mechanisms of tumor induced
lymphangiogenesis, that is, the formation of new lymphatic vessels.
It is currently thought that the main mechanism causing the formation of new lymphatic vessels is mediated by
a paracrine lymphangiogenic factor VEGF-C that activates its receptor VEGFR-3 expressed in lymphatic
endothelial cells. We recently discovered a fundamentally different mechanism of tumor lymphangiogenesis
that complements the current views. This mechanism is mediated by tumor-mobilized bone marrow (BM)-
derived monocytic progenitors that upon influence of the inflammatory tumor environment differentiate into
lymphatic-like cells. These cells dubbed here Monocyte-derived Lymphatic Endothelial Cells Progenitors or M-
LECP are characterized by the two main traits: (1) co-expression of myeloid and lymphatic-specific proteins
that are typically segregated into distinct lineages; and (2) the ability to integrate into preexisting lymphatic
vessels, which is an early prerequisite for lymphatic outgrowth.
Using these criteria, we found very high levels of M-LECP in blood and tumors of BC patients as well as in a
variety of metastatic orthotopic breast tumors from human and mouse origins. All tumors that contained M-
LECP also displayed lymphatic vessels positive for myeloid-specific markers, an established phenomenon
indicative of vascular integration of M-LECP that is required for sprouting. Importantly, we recently established
that the levels of tumor-recruited M-LECP significantly correlate with tumor lymphatic density and lymph node
status in clinical BC patients. Our studies in BC models showed that M-LECP originate from BM-derived
CD11b+ cells that are highly positive for a lymphatic marker Podoplanin (Pdpn). Adoptive transfer of a
phenotypically distinct BM subset identified by CD11b and Pdpn from metastatic tumor-bearing mice to mice
with low-metastatic tumors significantly increased the density of lymphatic vessels and lymphatic metastasis.
Preliminary data also show that differentiation of M-LECP can be faithfully reproduced in vitro by activating
Toll-like Receptor-4 (TLR4) in human primary normal blood-circulating monocytes. This process is controlled
by NF-kB and a transcription factor c-Maf, a newly identified regulator of monocytic-lymphatic reprogramming.
TLR4-dependent upregulation of NF-kB and c-Maf leads to activation of the VEGFR-3 pathway which appears
to be a critical milestone for acquisition of the lymphatic phenotype. Based on these findings, we hypothesize
that tumor lymphatic outgrowth, an essential prerequisite for metastasis, is strongly promoted by M-
LECP differentiating from the bone marrow myeloid precursors by TLR4-activating factors.
To test this hypothesis we propose the following Specific Aims:
(1) Test the hypothesis that M-LECP are directly and significantly relate to tumor-induced lymphangiogenesis
and lymphatic metastasis in clinical BC; (2) Delineate the molecular mechanisms that reprogram bone marrow
myeloid precursors into M-LECP; and (3) Determine the role of TLR4 in generation of the CD11b+/Pdpn+ bone
marrow subset and its direct contribution to the formation of tumor lymphatic vessels and metastasis.
Impact and Translational Relevance:
We anticipate that these studies will establish a novel mechanism by which BM-derived monocytes recruited
by breast tumors promote lymphangiogenesis and metastasis to lymph nodes. Validation of this novel concept
will enhance the mechanistic understanding of the formation of tumor lymphatic vessels and suggest new
molecular targets for inhibiting differentiation of M-LECP. Additionally, detection of higher levels of tumor-
residing and blood-circulating M-LECP might identify BC patients with more aggressive tumors who should be
preemptively treated to suppress locoregional spread. Such study outcomes can bolster the current clinical
paradigms thus reducing mortality of BC patients.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sophia Ran其他文献
Sophia Ran的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sophia Ran', 18)}}的其他基金
Novel role of myeloid-derived lymphatic progenitors in induction of breast cancer lymphatics
髓源性淋巴祖细胞在诱导乳腺癌淋巴管中的新作用
- 批准号:
9304980 - 财政年份:2016
- 资助金额:
$ 33.74万 - 项目类别:
NF-kB mediated induction of VEGFR-3 and new lymphatic vessels in breast cancer
NF-kB 介导乳腺癌中 VEGFR-3 和新淋巴管的诱导
- 批准号:
8447366 - 财政年份:2010
- 资助金额:
$ 33.74万 - 项目类别:
NF-kB mediated induction of VEGFR-3 and new lymphatic vessels in breast cancer
NF-kB 介导乳腺癌中 VEGFR-3 和新淋巴管的诱导
- 批准号:
7891116 - 财政年份:2010
- 资助金额:
$ 33.74万 - 项目类别:
NF-kB mediated induction of VEGFR-3 and new lymphatic vessels in breast cancer
NF-kB 介导乳腺癌中 VEGFR-3 和新淋巴管的诱导
- 批准号:
8607514 - 财政年份:2010
- 资助金额:
$ 33.74万 - 项目类别:
NF-kB mediated induction of VEGFR-3 and new lymphatic vessels in breast cancer
NF-kB 介导乳腺癌中 VEGFR-3 和新淋巴管的诱导
- 批准号:
8212495 - 财政年份:2010
- 资助金额:
$ 33.74万 - 项目类别:
NF-kB mediated induction of VEGFR-3 and new lymphatic vessels in breast cancer
NF-kB 介导乳腺癌中 VEGFR-3 和新淋巴管的诱导
- 批准号:
8035876 - 财政年份:2010
- 资助金额:
$ 33.74万 - 项目类别:
Mechanisms of VEGF-A regulated tumor lymphangiogenesis
VEGF-A调节肿瘤淋巴管生成的机制
- 批准号:
7194794 - 财政年份:2007
- 资助金额:
$ 33.74万 - 项目类别:
相似海外基金
A methodology to connect functionalized gonadal constructs to a chick embryo through mechanically induced blood vessels from an egg
一种通过鸡蛋机械诱导血管将功能化性腺结构连接到鸡胚胎的方法
- 批准号:
24K15741 - 财政年份:2024
- 资助金额:
$ 33.74万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
All-in-One Smart Artificial Blood Vessels
一体化智能人造血管
- 批准号:
EP/X027171/2 - 财政年份:2024
- 资助金额:
$ 33.74万 - 项目类别:
Fellowship
Development of nextgeneration cellular artificial blood vessels for coronary artery bypass surgery using bio-3D printer
使用生物 3D 打印机开发用于冠状动脉搭桥手术的下一代细胞人造血管
- 批准号:
23H02991 - 财政年份:2023
- 资助金额:
$ 33.74万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
ealization of navigation surgery by automatic recognition of stomach and surrounding blood vessels using artificial intelligence
利用人工智能自动识别胃及周围血管,实现导航手术
- 批准号:
23K07176 - 财政年份:2023
- 资助金额:
$ 33.74万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Realtime observation and optical control of living microbial probes in blood vessels
血管内活微生物探针的实时观察和光学控制
- 批准号:
23H00551 - 财政年份:2023
- 资助金额:
$ 33.74万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
Creation of a technique for visualization of stress concentration in blood and blood vessels by combined measurement of photoelasticity and ultrasonic Doppler velocimetry
通过光弹性和超声多普勒测速的组合测量,创建了一种可视化血管中应力集中的技术
- 批准号:
23H01343 - 财政年份:2023
- 资助金额:
$ 33.74万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Shear stress-activated synthetic cells for targeted drug release in stenotic blood vessels
剪切应力激活合成细胞用于狭窄血管中的靶向药物释放
- 批准号:
10749217 - 财政年份:2023
- 资助金额:
$ 33.74万 - 项目类别:
Creation of 3D tissue culture system integrated with blood vessels and autonomic nerves
打造血管与植物神经融合的3D组织培养系统
- 批准号:
23H01827 - 财政年份:2023
- 资助金额:
$ 33.74万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Biological function of osteoporotic drugs on bone-specific blood vessels and perivascular cells
骨质疏松药物对骨特异性血管和血管周围细胞的生物学功能
- 批准号:
22K21006 - 财政年份:2022
- 资助金额:
$ 33.74万 - 项目类别:
Grant-in-Aid for Research Activity Start-up














{{item.name}}会员




